150109-42-5

Basic information

• Product Name: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, chloromethyl ester
• CAS NO: 150109-42-5
• Molecular Formula: C9H16ClNO4
• Molecular Weight: 237.683
• Mol File: 150109-42-5.mol

Chemical Properties

• CAS DataBase Reference: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, chloromethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, chloromethyl ester(150109-42-5)
• EPA Substance Registry System: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-, chloromethyl ester(150109-42-5)

Safety Data

• Hazardous Substances Data: 150109-42-5(Hazardous Substances Data)

Upstream product

• 15761-38-3 L-N-Boc-Ala 
• 74-97-5 chlorobromomethane 
• 42538-65-8 N-(tert-butoxycarbonyl)-(S)-alanine cesium salt 
• 49715-04-0 chlorosulfuric acid chloromethyl ester 

Downstream Products

• 1581704-61-1 (S)-((S,Z)-3-((2R,3S)-3-Carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanamido)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl2-(tert-butoxycarbonylamino)propanoate 
• 1133711-12-2 L-2-tert-butoxycarbonylamino-propionic acid 3-[2,6-dichloro-4-(6-cyano-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-phenoxy]-5-isopropyl-6-oxo-6H-pyridazin-1-ylmethyl ester 

Relevant articles and documents

Improved synthesis of amino acid and dipeptide chloromethyl esters using bromochloromethane

Peptide chloromethyl esters are important compounds in prodrug synthesis. A simple, mild and efficient method for the synthesis of chloromethyl esters of N-blocked amino acids and dipeptides using exclusively bromochloromethane is reported. These N-blocke

A simple preparation of chloromethyl esters of the blocked amino acids

An efficient synthesis of various chloromethyl esters of the blocked amino acids, very useful reagents for prodrug, are described.

POMALIDOMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR

Disclosed in the present invention are a Pomalidomide derivative and a preparation method therefor. Specifically, the present invention relates to the Pomalidomide derivative and a stereoisomer thereof, or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating cancers.

TERTIARY AMINE COMPOUND OR IMINE COMPOUND-POLYMER CONJUGATE AND PRODUCTION METHOD THEREFOR

Provided is a compound obtained by conjugating a tertiary amine compound or imine compound, which is useful as a drug, with a polymer, in which a structure D+ having a quaternary ammonium salt or iminium salt formed from a tertiary amine compound or imine compound D and a polymer residue Poly having a carboxy group are bonded to each other via a structure —C(R1)(R2)OC(O)ANHC(═O)—.

POMALIDOMIDE DERIVATIVES AND THE PREPARING METHOD THEREOF

The invention relates to pomalidomide derivatives and their stereoisomers or pharmaceutically acceptable salts, and their use in preparing medicaments for treating cancers.

NITRIC OXIDE DONORS

The present invention provides, in part a novel class of nonoate compounds which exhibit nitric oxide releasing activity and their pharmaceutically acceptable salts, esters and prodrugs. The compounds release nitric oxide upon activation by contact with plasma. The present invention also relates to the use of the disclosed compounds to deliver nitric oxide to treat disorders arising from nitric oxide dysregulation.

BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND PRODRUGS THEREOF

Disclosed are compounds of Formula (I) and/or salts thereof: wherein R1 is —CH2CH2CF3; R2 is —CH2CH2CF3 or —CH2CH2CH2CF3; R3 is H, —CH3, or Rx; R4 is H or Ry; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer; or as prodrugs of such compounds.

PRODRUGS OF 1,4-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I) and salts thereof, wherein: a) R1 is H or CH3, and R2 is Ry; or b) R1 is Rx and R2 is H; wherein Rx and Ry are disclosed herein.

PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE

In part, the present disclosure is directed to derivatives of (E)-N-methy1-N-(( 3-methylta 1,8-naphthyndin-3-y1)acrylamide compounds with significant solubility, solid state stability and bioavailability profiles. Said compounds have been found to be effective inhibitors of bacterial fatty acid metabolism via the effective inhibition of FabL hi addition, certain compounds are shown to be stable towards gamma radiation sterilization treatments, and are thus well-suited to the production of a sterile formulation for use in the treatment of illnesses caused by bacterial infections.

2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS

The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.